Latest News

CorMedix overview and recent share performance CorMedix (CRMD) has drawn investor attention after a sharp pullback over the past month, with the share price down about 38% and roughly 30% lower over the past 3 months. That recent weakness comes despite a 1 day return of 6.74% and a 14.45% move over the past week. This may prompt some investors to reassess how the current price compares with the company’s fundamentals. See our latest analysis for CorMedix. Looking beyond the recent bounce,...

Peoples Bancorp of North Carolina (PEBK) just closed out FY 2025 with fourth quarter revenue of US$24.6 million and EPS of US$1.25, alongside trailing 12 month revenue of US$89.1 million and EPS of US$3.74 that reflects 21.3% earnings growth over the past year. Over recent periods, the company has seen quarterly revenue move from US$21.1 million in Q4 2024 to US$24.6 million in Q4 2025, while quarterly EPS shifted from US$0.67 to US$1.25. This sets up a story where improving margins and a...

KBRA recently assigned preliminary credit ratings to 56 classes of mortgage-backed notes from PMT Loan Trust 2026-CNF1, a prime RMBS transaction backed by 576 agency-eligible, conforming mortgage loans sponsored by PennyMac Corp., an indirect wholly owned subsidiary of PennyMac Mortgage Investment Trust. This fresh securitization highlights PennyMac Mortgage Investment Trust’s continued use of mortgage-backed markets to finance conforming, general QM loans and potentially broaden its...

Why BBVA’s new share buyback matters for shareholders Banco Bilbao Vizcaya Argentaria (BME:BBVA) has launched a new share buyback initiative, a move that directly affects existing shareholders by reducing the share count and concentrating each investor’s claim on the bank’s €10,022m net income. See our latest analysis for Banco Bilbao Vizcaya Argentaria. The new buyback comes at a time when BBVA’s share price has been firm, with the stock at €21.33 and a 90 day share price return of 24.08%,...

U.S. Gold Corp recently advanced its CK Gold Project in Wyoming toward a Definitive Feasibility Study after securing US$31,000,000 in financing, while benefiting from record-high gold prices that enhance project economics and the perceived value of its Nevada and Idaho exploration assets. An interesting angle is how stronger gold prices can make mine-construction financing more attainable, potentially accelerating timelines for turning U.S.-based mineral resources into producing...

New Gold (TSX:NGD) is back in focus after reporting its 2025 operating and sales results, including full year production of 353,772 ounces of gold and 50.1 million pounds of copper, alongside robust consolidated metal sales. See our latest analysis for New Gold. The share price has moved sharply over the past few months, with a 37.95% 30 day share price return and a 93.88% 90 day share price return at a latest close of CA$17.12. The 1 year total shareholder return is very large, suggesting...

Sarepta Therapeutics (NasdaqGS:SRPT) reported positive 3 year data from the EMBARK Phase 3 study of Elevidys gene therapy in Duchenne muscular dystrophy. The results show sustained functional benefits in ambulatory Duchenne patients over 3 years with a manageable safety profile. No new safety issues were identified in the 3 year readout, addressing prior concerns around long term efficacy and safety. Sarepta Therapeutics focuses on genetic medicines for rare neuromuscular diseases, and...

If you are wondering whether BridgeBio Pharma's share price still makes sense after a strong run, this article focuses on what the numbers say about value rather than the excitement around the stock. The stock trades at US$77.81, with returns of 2.0% over the past week, 2.7% over the past month, a slight year to date decline of 0.5%, a 112.2% return over the past year, a very large 3 year gain that is around 7x, and a 35.5% return over 5 years. Recent news around BridgeBio has centered on...

Key Insights Significant control over Chennai Petroleum by public companies implies that the general public has more...

Piper Sandler Companies recently reported that over the past two years it has delivered strong annual growth in revenue, earnings per share, and tangible book value per share, all pointing to improved profitability and capital strength. What stands out is that earnings per share expansion has far outpaced revenue growth, implying meaningful efficiency gains and better operating leverage across the business. We’ll now examine how this outsized earnings growth, relative to revenue, may...

Chewy (NYSE:CHWY) has announced the retirement of its Chief Technology Officer, Satish Mehta. The leadership transition affects oversight of Chewy's technology platforms and product development efforts. Stakeholders are assessing what this change could mean for the company's future technology priorities. Chewy, trading at $31.43, has seen its share price under pressure, with a 7 day return of a 6.8% decline and a 1 year return of a 19.3% decline. Over 3 years, the stock has recorded a 27.3%...

Key Insights Institutions' substantial holdings in NHK Spring implies that they have significant influence over the...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

To the annoyance of some shareholders, Magle Chemoswed Holding AB (publ) ( STO:MAGLE ) shares are down a considerable...

Keystone Infra Ltd ( TLV:KSTN ) shares have continued their recent momentum with a 25% gain in the last month alone...

Key Insights Significant control over Infragreen Group by retail investors implies that the general public has more...

Key Insights The considerable ownership by retail investors in Syensqo indicates that they collectively have a greater...

The Westwing Group SE ( ETR:WEW ) share price has done very well over the last month, posting an excellent gain of 31...

With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Healthcare industry in Denmark, you could be...

Key Insights PetroNor E&P's significant private companies ownership suggests that the key decisions are influenced by...

Confinvest F.L. S.p.A. ( BIT:CFV ) shareholders would be excited to see that the share price has had a great month...

JOST Werke SE ( ETR:JST ), might not be a large cap stock, but it received a lot of attention from a substantial price...

Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Anyone who held Kaldvik AS ( OB:KLDVK...

There wouldn't be many who think Alumexx N.V.'s ( AMS:ALX ) price-to-sales (or "P/S") ratio of 0.5x is worth a mention...